Showing 51-60 of 254 results for "".
Noah Worcester 2024: Dr. Webster on Isotretinoin
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-webster-isotretinoin/24581/Guy Webster, MD, PhD, FAAD, summarizes his lecture on new developments in isotretinoin at the 2024 Noah Worcester Dermatological Society meeting.Novel PsO Drug Could Be 'Closest Perception of a Cure,' Dr. Strober Says at Maui Derm
https://practicaldermatology.com/programs/practical-dermatology/novel-pso-drug-could-be-closest-perception-of-a-cure-dr-strober-says-at-maui-derm/32922/A novel monoclonal antibody targeting IL-23 for the treatment of psoriasis offers an extended half-life that will be a key differentiator for patients, according to Bruce Strober, MD, PhD.Improving the After-Sun Treatment Market
https://practicaldermatology.com/series/c-suite-chats/improving-after-sun-treatment-market/29805/Ed Esquenazi, PhD, Founder and CEO of health and performance company, Terns, discusses the after-sun treatment market and two new products designed to combat inflammation and aging after exposure to the sun.Noah Worcester 2024: Dr. Gottlieb on Psoriatic Arthritis
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-gottlieb-psoriatic-arthritis/24594/Alice Gottlieb, MD, PhD, summarizes her lecture on the critical role of the dermatologist in preventing disability due to psoriatic arthritis at the 2024 Noah Worcester Dermatological Society meeting.Finally: JAK Inhibitors Are Here
https://practicaldermatology.com/topics/psoriasis/finally-jak-inhibitors-are-here/20076/JAK inhibitors reach across all of dermatology, says Brett King, MD, PhD, who says the existing data is impressive and even more data are forthcoming for this class of medicine that will "change the landscape of dermatology."How to Discuss Isotretinoin’s Safety Profile With Acne Patients
https://practicaldermatology.com/conferences/maui-derm-2024/how-to-discuss-isotretinoins-safety-profile-with-acne-patients/20237/Acne Symposium moderator Guy Webster, MD, PhD, clinical professor of dermatology at Thomas Jefferson University, explains how he helps adolescent patients with the most severe cases of acne manage the potential side effects of isotretinoin.Is Your Sunscreen Safe?
https://practicaldermatology.com/conferences/scale-2023/is-your-sunscreen-safe/20187/Practical Dermatology magazine's newest editorial advisory board member Christopher Bunick, MD, PhD, shares advice on how to choose benzene-free sunscreens and offers tips on making smarter choices about sun protection.Acne Treatment Strategies
https://practicaldermatology.com/conferences/maui-derm-2022/acne-treatment-strategies/20046/Guy F. Webster, MD, PhD shares acne management strategies that are effective for patients and help minimize use of antibiotics. He also discusses the continued role for isotretinoin for the right candidates.Chronic Hand Eczema Treatment Landscape
https://practicaldermatology.com/series/c-suite-chats/chronic-hand-eczema-treatment-landscape/29126/Jacob Thyssen, MD, PhD, Chief Scientific Officer at Leo Pharma, talks about the incidence of chronic hand eczema and the advantage that delgocitinib provides compared to other treatment options.Psoriasis Pipeline Update: JNJ-2113, A Novel Oral IL-23 Receptor Antagonist Peptide, Shows Promise in a Phase 2b Study
https://practicaldermatology.com/topics/psoriasis/psoriasis-pipeline-update-jnj-2113-a-novel-oral-il-23-receptor-antagonist-peptide-shows-promise-in-a-phase-2b-study/20207/Laura Korb Ferris, MD, PhD, discusses the topline results from a Phase 2b trial of JNJ-2113, a novel oral IL-23 receptor antagonist peptide that’s being developed for moderate-to-severe plaque psoriasis.